With the development of nanotechnology, various drug delivery systems including inorganic
nanoparticles, liposomes, polymers, etc. have been developed over the past decade. Some …

Despite the enormous therapeutic potential of siRNA as a treatment strategy, the delivery is
still a problem due to unfavorable biodistribution profiles and poor intracellular …

Over the past few years, efforts in developing efficient non-viral carriers for the intracellular
delivery of siRNA have become increasingly intensive, due to the great potentials exhibited …

The present study describes hybrid nanoparticles, built by alternate deposition of siRNA and
modified polyethyleneimine (tyrosine-grafted PEI or tyrosine/galactose-grafted PEI) on …

Small interfering RNAs (siRNA) are short nucleic acid fragments of about 20–27 nucleotides,
which can inhibit the expression of specific genes. siRNA based RNAi technology has …

It is generally believed that intravenous application of cationic vectors is limited by the
binding of abundant negatively charged serum components, which may cause rapid …

Resistance to platinum agents is a crucial challenge in the treatment of cancer using
platinum drugs. To overcome the resistance of cells, the survivin protein is supposed to be …

Poly γ-glutamic acid (γ-PGA) is attractive due to its desirable biological properties such as
nontoxicity, excellent biocompatibility, and minimal immunogenicity. Additionally, γ-PGA …

Gene therapy through intracellular delivery of a functional gene or a gene-silencing element
is a promising approach to properly treat critical human diseases like cancer. The ability of …

Activation of signal transducer and activator of transcription3 (STAT3) is a hallmark of
several types of cancer. Failure to inhibit STAT3 expression by injection of siRNA for STAT3 …